Effect of dipeptidyl peptidase-4 inhibitors on fat metabolism in patients with type 2 diabetes mellitus

Effect of dipeptidyl peptidase-4 inhibitors on fat metabolism in patients with type 2 diabetes mellitus

AIM. To evaluate the effect of sitagliptin in combination with metformin on glucose toxicity and lipotoxicity in patients with type 2 diabetes mellitus. MATERIALS AND METHODS. Eighty-two overweight and dyslipidemic patients (mean age 55.3±9.1 years) who had not achieved the goal levels of glycated h...

Podrobná bibliografie
Hlavní autoři:	A S Ametov, D G Gusenbekova
Médium:	Článek
Jazyk:	Russian
Vydáno:	"Consilium Medicum" Publishing house 2014-08-01
Edice:	Терапевтический архив
Témata:	type 2 diabetes mellitus dipeptidyl peptidase-4 inhibitors sitagliptin metformin fat metabolism
On-line přístup:	https://ter-arkhiv.ru/0040-3660/article/view/31576

Podobné jednotky

Nonglycemic effects of dipeptidyl peptidase-4 inhibitors
Autor: A S Ametov, a další
Vydáno: (2013-01-01)

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
Autor: Yayoi Nishida, a další
Vydáno: (2020-04-01)

The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity
Autor: Aleksander Sergeevich Ametov, a další
Vydáno: (2015-10-01)

Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus
Autor: Choi YJ, a další
Vydáno: (2019-08-01)

The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo
Autor: Masako Uchii, a další
Vydáno: (2017-11-01)

Dipeptidyl Peptidase 4 (DPP4) as A Novel Adipokine: Role in Metabolism and Fat Homeostasis
Autor: Ilaria Barchetta, a další
Vydáno: (2022-09-01)

Factors associated with the glucose‐lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials
Autor: Naoko Tajima, a další
Vydáno: (2020-05-01)

Study on Anti-inflammatory and Anti-oxidative Stress Mechanism of Sitagliptin: a Dipeptidyl Peptidase-4 Inhibitor
Autor: ZHU Jing, XIE Ji, HU Xiaoxia
Vydáno: (2025-04-01)

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, β-Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who are Treatment Naïve or Poorly Responsive to Antidiabetes Agents: A Multicenter, Prospective Observational, Uncontrolled Study
Autor: Yuya Tsurutani, MD, PhD, a další
Vydáno: (2017-01-01)

Angioprotektivnoe properties lowering drugs from the group of inhibitors of dipeptidyl peptidase-4
Autor: E V Oskola, a další
Vydáno: (2013-09-01)

Dipeptidyl peptidase-4 inhibitors alleviate cognitive dysfunction in type 2 diabetes mellitus
Autor: Jie Meng, a další
Vydáno: (2023-12-01)

The multiple actions of dipeptidyl peptidase 4 (DPP-4) and its pharmacological inhibition on bone metabolism: a review
Autor: L. M. Pechmann, a další
Vydáno: (2024-07-01)

Time to exacerbation of heart failure is longer in Malaysian population on dipeptidyl peptidase-4 inhibitor
Autor: J Hasan, a další
Vydáno: (2017-01-01)

Association between dipeptidyl peptidase-4 inhibitors use and leptin in type 2 diabetes mellitus
Autor: Xin Wei, a další
Vydáno: (2021-08-01)

Dipeptidyl peptidase 4 inhibitors in modern domestic practice
Autor: A. S. Ametov, a další
Vydáno: (2020-05-01)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
Autor: Gagik Radikovich Galstyan, a další
Vydáno: (2015-12-01)

The Effect of Dipeptidyl Peptidase-4 Inhibitors on Macrovascular and Microvascular Complications of Diabetes Mellitus: A Systematic Review
Autor: Olesya M. Taylor, PharmD, BCPS, a další
Vydáno: (2020-01-01)

The influence of dipeptidyl peptidase-4 inhibitor on the progression of type B intramural hematoma
Autor: Qu Chen, a další
Vydáno: (2022-10-01)

Association between Dipeptidyl Peptidase-4 Inhibitor Prescription and Erythropoiesis-Stimulating Agent Hyporesponsiveness in Hemodialysis Patients with Diabetes Mellitus
Autor: Takeshi Hasegawa, a další
Vydáno: (2021-04-01)

Effect of Dipeptidyl-Peptidase 4 Inhibitors on Circulating Oxidative Stress Biomarkers in Patients with Type 2 Diabetes Mellitus
Autor: Elisabetta Bigagli, a další
Vydáno: (2020-03-01)

Dynamics of total volume of pancreatic α‐ and β ‐cells under the influence sulfonylureas and their combination with dipeptidyl peptidase‐4 inhibitors
Autor: Tuchina Taisiia Pavlovna, a další
Vydáno: (2021-07-01)

Ocular cicatricial pemphigoid following Dipeptidyl Peptidase-4 inhibitor use: A case report
Autor: Akifumi Matsumoto, a další
Vydáno: (2023-12-01)

Effect of dipeptidyl peptidase-4 inhibitors on tumor necrosis factor alpha levels in patients with type 2 diabetes mellitus
Autor: Lijia Zhao, a další
Vydáno: (2024-07-01)

The effect of sitagliptin on hepatic ischemic reperfusion injury in rats
Autor: Song-Chol Mun, a další
Vydáno: (2020-01-01)

Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors
Autor: Sangmo Hong, a další
Vydáno: (2022-01-01)

The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort study
Autor: Shin S, a další
Vydáno: (2016-03-01)

Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication
Autor: Yasutake Shinohara, a další
Vydáno: (2020-10-01)

Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
Autor: Lin YH, a další
Vydáno: (2019-12-01)

The effect of metformin or dipeptidyl peptidase 4 inhibitors on clinical outcomes in metastatic non‐small cell lung cancer treated with immune checkpoint inhibitors
Autor: Jieun Yang, a další
Vydáno: (2023-01-01)

Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis
Autor: Dan Liu, a další
Vydáno: (2019-03-01)

A review on cardiovascular outcome studies of dipeptidyl peptidase-4 inhibitors
Autor: Maneesha Khalse, a další
Vydáno: (2018-01-01)

Association of dipeptidyl peptidase‐4 inhibitor use and risk of pancreatic cancer in individuals with diabetes in Japan
Autor: Sodai Kubota, a další
Vydáno: (2023-01-01)

DIPEPTIDYL DIPEPTIDASE-4: VIEW OF THE CLINICAL PHARMACOLOGIST
Autor: N. B. LAZAREVA
Vydáno: (2016-12-01)

Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
Autor: Wang N, a další
Vydáno: (2019-08-01)

The roles of dipeptidyl peptidase-4 inhibitors in prognosis of COVID-19 infection in patients with type 2 diabetes mellitus
Autor: Mohammad Sadidi, a další
Vydáno: (2022-01-01)

Dipeptidyl peptidase IV and its implication in cancer
Autor: Yarini M Arrebola, a další

The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study
Autor: Vaia Lambadiari, a další
Vydáno: (2021-02-01)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
Autor: Han E, a další
Vydáno: (2020-11-01)

Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies
Autor: Dimitrios Patoulias, a další
Vydáno: (2021-08-01)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
Autor: Green J, a další
Vydáno: (2010-10-01)